

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. SSM Health Cardinal Glennon Children's Hospital 2. 1465 S Grand Blvd. St. Louis, MO 63104		In accordance with application dated April 30, 2021, 3. License No.: 24-32264-01 is renewed in its entirety to read as follows:	4. Expiration Date: June 30, 2036 5. Docket No.: 030-35553 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Yttrium-90 permitted by 10 CFR 35.1000	7. Chemical and/or physical form A. Any B. Any C. Any D. Microspheres (Sirtex Wilmington LLC, Model Sirtex Medical SIR-Spheres microspheres)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 1 curie total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For use in permanent brachytherapy in a Sirtex Wilmington LLC SIR-Spheres delivery system permitted by 10 CFR 35.1000.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-32264-01

Docket or Reference No.:
030-35553

Amendment No. 10

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at 1465 S Grand Blvd., St. Louis, Missouri, 63104.
11. The Radiation Safety Officer (RSO) for this license is Wallace Fuhrman, BA, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|---|
| Razi Muzaffar, D.O. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Medhat M. Osman, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Keith Pereira, M.D. | 10 CFR 35.1000 (limited to yttrium-90 SIR-Sphere delivery system) |
| Kirubahara Vaheesan, M.D. | 10 CFR 35.1000 (limited to yttrium-90 SIR-Sphere delivery system) |


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-32264-01

Amendment No. 10

Docket or Reference No.:
030-35553

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated April 30, 2021 (ML21144A158)
 - B. Letter dated May 12, 2021 (ML21139A106)
 - C. Letter dated May 26, 2021 (ML21148A105)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 28, 2021By: _____
Cassandra F. Frazier
Region 3